BARDELLI, Alberto
 Distribuzione geografica
Continente #
NA - Nord America 10.368
EU - Europa 8.741
AS - Asia 6.633
OC - Oceania 385
SA - Sud America 281
AF - Africa 158
Continente sconosciuto - Info sul continente non disponibili 17
Totale 26.583
Nazione #
US - Stati Uniti d'America 9.834
CN - Cina 3.704
IT - Italia 2.769
DE - Germania 1.205
GB - Regno Unito 1.001
JP - Giappone 674
FR - Francia 669
ES - Italia 502
NL - Olanda 498
CA - Canada 456
CZ - Repubblica Ceca 383
KR - Corea 353
IN - India 347
AU - Australia 328
HK - Hong Kong 300
RU - Federazione Russa 245
IL - Israele 234
CH - Svizzera 162
VN - Vietnam 162
TR - Turchia 159
BR - Brasile 158
IE - Irlanda 154
BE - Belgio 141
PL - Polonia 133
SE - Svezia 126
TW - Taiwan 124
SG - Singapore 114
RO - Romania 100
DK - Danimarca 95
GR - Grecia 93
MY - Malesia 73
PT - Portogallo 72
TH - Thailandia 67
MX - Messico 66
ID - Indonesia 62
HU - Ungheria 61
AT - Austria 60
UA - Ucraina 57
NZ - Nuova Zelanda 56
ZA - Sudafrica 56
IR - Iran 49
CL - Cile 44
FI - Finlandia 39
NO - Norvegia 36
SA - Arabia Saudita 33
PH - Filippine 29
PK - Pakistan 28
SZ - Regno dello Swaziland 27
CO - Colombia 26
AR - Argentina 23
EG - Egitto 23
MO - Macao, regione amministrativa speciale della Cina 21
RS - Serbia 21
MK - Macedonia 20
JO - Giordania 18
PE - Perù 15
HR - Croazia 14
SI - Slovenia 14
SK - Slovacchia (Repubblica Slovacca) 13
LV - Lettonia 12
AE - Emirati Arabi Uniti 9
BD - Bangladesh 8
DZ - Algeria 8
IQ - Iraq 8
LB - Libano 8
LU - Lussemburgo 8
MA - Marocco 8
TN - Tunisia 8
BG - Bulgaria 7
BY - Bielorussia 7
EU - Europa 7
EC - Ecuador 6
ET - Etiopia 6
KZ - Kazakistan 6
LT - Lituania 6
NG - Nigeria 6
PR - Porto Rico 6
PS - Palestinian Territory 6
AP - ???statistics.table.value.countryCode.AP??? 5
KH - Cambogia 5
KW - Kuwait 5
BN - Brunei Darussalam 4
CY - Cipro 4
EE - Estonia 4
IS - Islanda 4
LY - Libia 4
QA - Qatar 4
A1 - Anonimo 3
BO - Bolivia 3
BT - Bhutan 3
KE - Kenya 3
UG - Uganda 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
CM - Camerun 2
LK - Sri Lanka 2
MN - Mongolia 2
MT - Malta 2
Totale 26.557
Città #
Houston 699
Fairfield 673
Beijing 540
Ashburn 519
Shanghai 478
Seattle 447
Torino 443
Ann Arbor 396
Santa Cruz 391
Buffalo 387
Woodbridge 345
Cambridge 315
Guangzhou 291
Hangzhou 260
Milan 242
Wilmington 241
Turin 202
Wuhan 194
Nanjing 165
Tokyo 161
New York 154
Rome 145
Chicago 128
Los Angeles 114
Dong Ket 113
University Park 113
Dublin 109
Barcelona 108
Chengdu 108
London 101
Mountain View 100
Central District 99
San Diego 96
Taipei 94
Central 87
Duncan 82
Ottawa 82
Changsha 81
Fleming Island 81
Tel Aviv 81
Shenyang 80
Amsterdam 76
Paris 76
Sabadell 75
Boston 68
Seoul 68
Pisa 66
Redmond 65
Toronto 64
Carrara 61
Nürnberg 59
Warsaw 58
Jinan 57
Las Vegas 55
Melbourne 55
Dallas 51
Lake Forest 51
Brescia 50
Council Bluffs 50
Boardman 49
Manchester 49
Philadelphia 48
Fuzhou 47
Norwalk 47
Tianjin 47
Utrecht 47
Clearwater 45
Singapore 45
Xian 45
Chongqing 44
Phoenix 44
San Francisco 43
San Jose 43
Muizenberg 39
Ankara 38
Hefei 38
Istanbul 38
Madrid 37
Munich 37
Rochester 37
Berlin 36
Stockholm 36
Baltimore 35
Mumbai 35
Simi Valley 35
Vienna 35
Brussels 34
Sydney 34
Brisbane 33
Changchun 33
Jakarta 33
Birmingham 32
Hamilton 32
Nanchang 32
Seongnam 31
Zurich 31
Delhi 30
Heidelberg 29
Leawood 29
Riva 29
Totale 12.211
Nome #
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, file e27ce426-e257-2581-e053-d805fe0acbaa 2.706
High-dose Vitamin C enhances cancer immunotherapy, file e27ce42f-de1f-2581-e053-d805fe0acbaa 2.294
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial, file e27ce42a-9a18-2581-e053-d805fe0acbaa 1.966
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma., file e27ce426-f515-2581-e053-d805fe0acbaa 1.549
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer, file e27ce430-1013-2581-e053-d805fe0acbaa 1.088
Adaptive mutability of colorectal cancers in response to targeted therapies, file e27ce42e-f361-2581-e053-d805fe0acbaa 875
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce42c-7e04-2581-e053-d805fe0acbaa 752
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer, file e27ce426-f447-2581-e053-d805fe0acbaa 672
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution., file e27ce427-09bb-2581-e053-d805fe0acbaa 552
BRAF V600E is a determinant of sensitivity to proteasome inhibitors., file e27ce426-ffd1-2581-e053-d805fe0acbaa 476
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities, file e27ce428-d7aa-2581-e053-d805fe0acbaa 433
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, file e27ce42c-ac40-2581-e053-d805fe0acbaa 405
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer, file e27ce42e-fdba-2581-e053-d805fe0acbaa 361
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer, file e27ce42c-833b-2581-e053-d805fe0acbaa 327
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, file e27ce426-f0f2-2581-e053-d805fe0acbaa 316
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model, file e27ce426-9df8-2581-e053-d805fe0acbaa 315
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer, file e27ce42b-4659-2581-e053-d805fe0acbaa 304
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, file e27ce427-2d1b-2581-e053-d805fe0acbaa 292
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs, file e27ce428-9f58-2581-e053-d805fe0acbaa 276
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma, file e27ce42b-34b3-2581-e053-d805fe0acbaa 266
Minimal residual disease in breast cancer: in blood veritas., file e27ce426-f514-2581-e053-d805fe0acbaa 257
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, file e27ce426-9d7d-2581-e053-d805fe0acbaa 243
Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer, file e27ce428-9c8e-2581-e053-d805fe0acbaa 236
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-ad33-2581-e053-d805fe0acbaa 236
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer, file e27ce426-d50c-2581-e053-d805fe0acbaa 223
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions, file e27ce42b-9069-2581-e053-d805fe0acbaa 221
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, file e27ce42a-9432-2581-e053-d805fe0acbaa 218
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo letter, file e27ce42e-896e-2581-e053-d805fe0acbaa 209
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9706-2581-e053-d805fe0acbaa 204
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer, file e27ce42b-fd7d-2581-e053-d805fe0acbaa 204
Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature, file e27ce42c-9a05-2581-e053-d805fe0acbaa 195
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients, file e27ce427-0386-2581-e053-d805fe0acbaa 187
Exploiting DNA repair defects in colorectal cancer, file e27ce42d-e5d7-2581-e053-d805fe0acbaa 187
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file e27ce428-ee7a-2581-e053-d805fe0acbaa 186
Somatic alterations as the basis for resistance to targeted therapies, file e27ce428-9f6e-2581-e053-d805fe0acbaa 179
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells., file e27ce426-f1b3-2581-e053-d805fe0acbaa 173
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients, file e27ce435-9a5d-2581-e053-d805fe0acbaa 171
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, file e27ce426-de44-2581-e053-d805fe0acbaa 167
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance., file e27ce427-09b8-2581-e053-d805fe0acbaa 165
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, file e27ce428-9c1b-2581-e053-d805fe0acbaa 163
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells., file e27ce427-09b7-2581-e053-d805fe0acbaa 162
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway, file e27ce428-9ade-2581-e053-d805fe0acbaa 156
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, file e27ce42e-7735-2581-e053-d805fe0acbaa 152
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases, file e27ce42c-7e06-2581-e053-d805fe0acbaa 150
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer, file ec9c2092-a53b-4286-be12-aa515de4f3e9 149
Mutational profiling of kinases in glioblastoma., file e27ce427-09ba-2581-e053-d805fe0acbaa 148
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, file e27ce428-f6ea-2581-e053-d805fe0acbaa 145
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS, file e27ce426-d43e-2581-e053-d805fe0acbaa 144
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file e27ce42c-4ba9-2581-e053-d805fe0acbaa 143
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer, file e27ce426-b3ca-2581-e053-d805fe0acbaa 138
Preclinical models for precision oncology, file e27ce42e-972c-2581-e053-d805fe0acbaa 138
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case, file e27ce42c-564d-2581-e053-d805fe0acbaa 133
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia, file e27ce426-e4f1-2581-e053-d805fe0acbaa 131
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, file e27ce42b-34b0-2581-e053-d805fe0acbaa 131
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, file e27ce42a-d37f-2581-e053-d805fe0acbaa 130
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients, file e27ce42a-d380-2581-e053-d805fe0acbaa 130
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients, file e27ce42b-34b5-2581-e053-d805fe0acbaa 125
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group, file e27ce433-cdb4-2581-e053-d805fe0acbaa 125
Early-onset colorectal cancer in young individuals, file e27ce42d-e4e5-2581-e053-d805fe0acbaa 119
Toward understanding and exploiting tumor heterogeneity, file e27ce428-d0ff-2581-e053-d805fe0acbaa 114
Evolving neoantigen profiles in colorectal cancers with DNA repair defects, file e27ce42e-a91a-2581-e053-d805fe0acbaa 107
How liquid biopsies can change clinical practice in oncology, file e27ce42f-a2de-2581-e053-d805fe0acbaa 104
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance, file e27ce42c-b2a5-2581-e053-d805fe0acbaa 102
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib., file e27ce42e-9c36-2581-e053-d805fe0acbaa 101
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects., file e27ce426-bd45-2581-e053-d805fe0acbaa 100
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial, file e27ce430-cb73-2581-e053-d805fe0acbaa 100
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file e27ce429-176a-2581-e053-d805fe0acbaa 97
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer, file e27ce435-6233-2581-e053-d805fe0acbaa 97
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy., file e27ce426-df59-2581-e053-d805fe0acbaa 95
Exploring the links between cancer and placenta development, file e27ce42d-687c-2581-e053-d805fe0acbaa 94
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies, file e27ce42d-8304-2581-e053-d805fe0acbaa 92
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer, file e27ce42f-ed2c-2581-e053-d805fe0acbaa 90
TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma, file e27ce42f-6ed8-2581-e053-d805fe0acbaa 86
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer, file e27ce429-c87b-2581-e053-d805fe0acbaa 85
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file e27ce427-3a7d-2581-e053-d805fe0acbaa 83
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility, file e27ce429-02da-2581-e053-d805fe0acbaa 82
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer, file e27ce429-1433-2581-e053-d805fe0acbaa 82
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ, file e27ce431-d28a-2581-e053-d805fe0acbaa 79
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer, file e27ce42b-6238-2581-e053-d805fe0acbaa 78
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer, file e27ce42c-9243-2581-e053-d805fe0acbaa 78
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer, file e27ce42c-e1e1-2581-e053-d805fe0acbaa 78
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways, file e27ce432-6e6c-2581-e053-d805fe0acbaa 77
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin, file e27ce435-7e08-2581-e053-d805fe0acbaa 77
Inactivation of DNA repair-prospects for boosting cancer immune surveillance, file e27ce42d-b681-2581-e053-d805fe0acbaa 76
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer, file e27ce430-7fc7-2581-e053-d805fe0acbaa 76
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors, file 2a9b9aad-9b03-41b3-9423-b8b115aae403 74
MET mutations in cancers of unknown primary origin (CUPs)., file e27ce426-ca6b-2581-e053-d805fe0acbaa 73
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours, file e27ce42e-2a00-2581-e053-d805fe0acbaa 70
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial, file e27ce42c-564c-2581-e053-d805fe0acbaa 68
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy, file e27ce432-19bb-2581-e053-d805fe0acbaa 67
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation, file e27ce432-7140-2581-e053-d805fe0acbaa 67
BRAF V600E is a determinant of sensitivity to proteasome inhibitors., file e27ce426-ffd2-2581-e053-d805fe0acbaa 66
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients, file e27ce42b-6c73-2581-e053-d805fe0acbaa 63
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-c004-2581-e053-d805fe0acbaa 61
Tracking colorectal cancer evolution in time and space, file e27ce42c-1eea-2581-e053-d805fe0acbaa 60
Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids, file e27ce432-8c4d-2581-e053-d805fe0acbaa 59
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3., file e27ce426-f670-2581-e053-d805fe0acbaa 57
Kras mutations and resistance to anti-egfr treatment, file e27ce426-9d7f-2581-e053-d805fe0acbaa 55
null, file e27ce430-cb75-2581-e053-d805fe0acbaa 55
Tumor evolution as a therapeutic target, file e27ce42c-66d9-2581-e053-d805fe0acbaa 54
Totale 26.177
Categoria #
all - tutte 36.511
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.511


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.569 0 0 0 0 0 0 0 267 222 314 426 340
2019/20204.098 311 227 232 411 302 276 322 370 460 362 385 440
2020/20215.737 365 466 473 461 504 527 449 423 573 588 452 456
2021/20226.369 517 444 551 661 649 458 454 460 624 363 696 492
2022/20236.204 295 382 875 789 526 477 634 650 708 526 296 46
2023/2024535 45 64 82 31 61 61 98 93 0 0 0 0
Totale 27.419